Fulminant Herpes Simplex Hepatitis Secondary to Adalimumab in Crohn's Disease: A Case Report.
Kanika GoelMark BunkerAnna BalogJan F SilvermanPublished in: Clinical medicine insights. Case reports (2019)
Herpes simplex virus (HSV) hepatitis is an uncommon cause of fulminant hepatic failure, seen mostly in immunocompromised patients. Conventional treatment modalities for inflammatory bowel disease (IBD), such as steroids and azathioprine, have been known to cause HSV hepatitis. However, the reported incidence of HSV hepatitis in IBD patients undergoing tumor necrosis factor (TNF)-α inhibitor therapy is very rare. In this case report, we describe a rare case of fulminant HSV hepatitis that developed in a patient with Crohn's disease after treatment with the TNF-α inhibitor, adalimumab.
Keyphrases
- herpes simplex virus
- rheumatoid arthritis
- case report
- rare case
- patients undergoing
- ulcerative colitis
- end stage renal disease
- ejection fraction
- risk factors
- chronic kidney disease
- liver failure
- stem cells
- intensive care unit
- prognostic factors
- juvenile idiopathic arthritis
- mesenchymal stem cells
- bone marrow
- combination therapy
- patient reported
- hidradenitis suppurativa